secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001558370-23-000362
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma enters $40M ATM equity facility with Jefferies, prepays $10M Oxford loan
--------------------------------------------------------------------------------

- New Open Market Sale Agreement with Jefferies for up to $40M in common stock at market prices; Jefferies gets up to 3% commission.
- Prior $75M ATM facility fully utilized (565,974 shares sold for $75M gross proceeds); terminated Jan 10, 2023.
- Company notified Oxford Finance of intent to prepay $5M by June 30, 2023 and $5M by Jan 31, 2024, reducing loan principal to ~$34M.
- Prepayments include final payment fees and accrued interest; scheduled for Feb 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/0001558370-23-000362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/kala-20230118x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer